Withings Unveils Advanced Body Scan Scale

Enhanced Tracking for Heart Wellness

In 2023, Withings introduced a high-end scale named Body Scan, integrated with technology reminiscent of sophisticated gyms or clinics. This device came equipped with a six-lead ECG, offered detailed analysis of body composition, and could observe various aspects of nerve health, among multiple features. At CES 2026 in Las Vegas, Withings presented their next-generation model, now capable of testing for hypertension and cellular health. The company aims to provide users with more comprehensive data to combat lifestyle-related chronic diseases.

Expanded Biomarker Checking

The original Body Scan could measure 40 biomarkers, whereas this new iteration can handle 60. Press materials now feature a bullet-point list to highlight these enhancements. At the forefront of new features is Impedance Cardiography (ICG), evaluating the heart's ability to circulate blood efficiently. Additionally, Bioimpedance Spectroscopy (BIS) employs a subtle electrical charge to assess total body water, assessing factors like cellular age, active cell content, and metabolic function.

Data-Driven Health Predictions

This wealth of information is processed by Withings' proprietary AI model, validated for clinical use, providing deeper insights such as hypertension risks and blood sugar regulation. Based on vital statistics, users receive predictions about their health journey, along with guidance on extending their healthy years. Essentially, Withings envisions this scale as an all-in-one health solution, nudging users toward healthier living.

Design Innovations

One significant update from the first model includes a retractable handle now doubling as the scale's display, ostensibly simplifying the reading process for users stepping onto the scale. Despite this improvement, there is concern regarding the fragility of the connection between the handle and the main unit's cable.

Market Release and Pricing

Withings plans to have the Body Scan 2 approved by the FDA, aiming for a release in the second quarter of 2026. Potential buyers should brace for the cost, as this premium device is priced at $599.95, €499.95, or £449.95, contingent on the region.